Structures of translationally inactive mammalian ribosomes
- Harvard Medical School, United States
- MRC Laboratory of Molecular Biology, United Kingdom
Abstract
The cellular levels and activities of ribosomes directly regulate gene expression during numerous physiological processes. The mechanisms that globally repress translation are incompletely understood. Here, we use electron cryomicroscopy to analyze inactive ribosomes isolated from mammalian reticulocytes, the penultimate stage of red blood cell differentiation. We identify two types of ribosomes that are translationally repressed by protein interactions. The first comprises ribosomes sequestered with elongation factor 2 (eEF2) by SERPINE mRNA binding protein 1 (SERBP1) occupying the ribosomal mRNA entrance channel. The second type are translationally repressed by a novel ribosome-binding protein, interferon-related developmental regulator 2 (IFRD2), which spans the P and E sites and inserts a C-terminal helix into the mRNA exit channel to preclude translation. IFRD2 binds ribosomes with a tRNA occupying a noncanonical binding site, the 'Z site', on the ribosome. These structures provide functional insights into how ribosomal interactions may suppress translation to regulate gene expression.
Data availability
All cryo-EM maps and models have been deposited in EMDB under accession codes 9234, 9235, 9236, 9237, 9239, 9240, 9241 and 9242. All models have been deposited in PDB under accession codes 6MTB, 6MTC, 6MTD and 6MTE.
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9234).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9235).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9236).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9237).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9239).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9240).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9241).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the EMBL-EBI Protein Data Bank (accession no: EMD-9242).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the RCSB Protein Data Bank (accession no: 6MTB).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the RCSB Protein Data Bank (accession no: 6MTC).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the RCSB Protein Data Bank (accession no: 6MTD).
-
Data from: Structures of translationally inactive mammalian ribosomesPublicly available at the RCSB Protein Data Bank (accession no: 6MTE).
Article and author information
Author details
Funding
Harvard Medical School (N/A)
- Alan Brown
- Matthew R Baird
- Matthew CJ Yip
- Sichen Shao
International Retinal Research Foundation (N/A)
- Alan Brown
E. Matilda Ziegler Foundation for the Blind (N/A)
- Alan Brown
Charles H. Hood Foundation (N/A)
- Sichen Shao
Richard and Susan Smith Family Foundation (N/A)
- Sichen Shao
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Nahum Sonenberg, McGill University, Canada
Version history
- Received: July 26, 2018
- Accepted: October 12, 2018
- Accepted Manuscript published: October 24, 2018 (version 1)
- Version of Record published: November 9, 2018 (version 2)
Copyright
© 2018, Brown et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 7,684
- views
-
- 1,061
- downloads
-
- 89
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Structures of translationally inactive mammalian ribosomes
eLife 7:e40486.
https://doi.org/10.7554/eLife.40486
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.
-
- Structural Biology and Molecular Biophysics
We integrate evolutionary predictions based on the neutral theory of molecular evolution with protein dynamics to generate mechanistic insight into the molecular adaptations of the SARS-COV-2 spike (S) protein. With this approach, we first identified candidate adaptive polymorphisms (CAPs) of the SARS-CoV-2 S protein and assessed the impact of these CAPs through dynamics analysis. Not only have we found that CAPs frequently overlap with well-known functional sites, but also, using several different dynamics-based metrics, we reveal the critical allosteric interplay between SARS-CoV-2 CAPs and the S protein binding sites with the human ACE2 (hACE2) protein. CAPs interact far differently with the hACE2 binding site residues in the open conformation of the S protein compared to the closed form. In particular, the CAP sites control the dynamics of binding residues in the open state, suggesting an allosteric control of hACE2 binding. We also explored the characteristic mutations of different SARS-CoV-2 strains to find dynamic hallmarks and potential effects of future mutations. Our analyses reveal that Delta strain-specific variants have non-additive (i.e., epistatic) interactions with CAP sites, whereas the less pathogenic Omicron strains have mostly additive mutations. Finally, our dynamics-based analysis suggests that the novel mutations observed in the Omicron strain epistatically interact with the CAP sites to help escape antibody binding.
